Director Blake Borgeson of Recursion Pharmaceuticals Inc (RXRX, Financial) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at a stock price of $10.58 per share, resulting in a total sale amount of $212,171.32.
Recursion Pharmaceuticals Inc is a biotechnology company that combines experimental biology and bioinformatics with artificial intelligence to discover new therapeutic opportunities. The company's platform is designed to rapidly discover novel compounds that could potentially treat a range of diseases, with a focus on genetic diseases and cancers.
Over the past year, the insider has sold a total of 286,075 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a broader trend observed within the company's insider transaction history.
The insider transaction history for Recursion Pharmaceuticals Inc shows a pattern of insider activity. In the past year, there have been 9 insider buys and 70 insider sells. This trend is visualized in the following insider trend image:
On the valuation front, Recursion Pharmaceuticals Inc's shares were trading at $10.58 on the day of the insider's sale, giving the company a market capitalization of $2.208 billion. The stock's price-to-GF-Value ratio stands at 0.41, indicating that the stock is significantly undervalued according to the GF Value metric. The GF Value of $25.66 suggests a substantial margin between the current share price and the estimated intrinsic value.
The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts. The GF Value for Recursion Pharmaceuticals Inc is depicted in the image below:
Investors and analysts often monitor insider transactions as they can provide insights into a company's internal perspective on the stock's valuation and future prospects. The recent sale by Director Blake Borgeson may attract attention from the market, considering the current undervaluation signal based on the GF Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
